Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients with histological confirmed epithelia ovarian cancer

• Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.

• Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting

• FFPE tumor tissue available

Locations
United States
Massachusetts
Dana-Farber Cancer Institute
COMPLETED
Boston
Oklahoma
OU Health Stephenson Cancer Center
RECRUITING
Oklahoma City
Washington
Swedish Center for Research and Innovation
RECRUITING
Seattle
Other Locations
United Kingdom
Beatson West of Scotland Cancer Centre
ACTIVE_NOT_RECRUITING
Glasgow
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
ACTIVE_NOT_RECRUITING
London
Contact Information
Primary
US: Kathleen Moore
KathleenMoore@ouhealth.com
+1 405-271-8707
Backup
Europe: Rebecca Kristeleit
Rebecca.Kristeleit@gstt.nhs.uk
Time Frame
Start Date: 2019-04-11
Estimated Completion Date: 2026-12
Participants
Target number of participants: 60
Treatments
Ovarian cancer patients
with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
Related Therapeutic Areas
Sponsors
Collaborators: Amarex Clinical Research
Leads: Allarity Therapeutics

This content was sourced from clinicaltrials.gov